{"id":20335,"date":"2021-07-02T09:00:59","date_gmt":"2021-07-02T09:00:59","guid":{"rendered":"https:\/\/dev2.btitrainingcenter.com\/use-of-plasma-rich-in-growth-factors-and-regenerating-agent-matrix-for-the-treatment-of-corneal-diseases\/"},"modified":"2025-03-17T14:23:10","modified_gmt":"2025-03-17T13:23:10","slug":"use-of-plasma-rich-in-growth-factors-and-regenerating-agent-matrix-for-the-treatment-of-corneal-diseases","status":"publish","type":"post","link":"https:\/\/www.btitrainingcenter.com\/fr\/use-of-plasma-rich-in-growth-factors-and-regenerating-agent-matrix-for-the-treatment-of-corneal-diseases\/","title":{"rendered":"Use of Plasma Rich in Growth Factors and ReGeneraTing Agent Matrix for the Treatment of Corneal Diseases"},"content":{"rendered":"

[vc_row content_text_aligment=”left” row_background_lines=”no”][vc_column][vc_column_text]<\/p>\n

Abstract<\/h3>\n
\n
\n
\n

This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers. RGTA treatment was applied (one drop every two days); however, if ulcer closure was not achieved, PRGF eye drops treatment was added (four times\/day). The time taken to reach the ulcer closure, the Best Corrected Visual Acuity (BCVA), intraocular pressure (IOP), Visual Analog Scale (VAS, in terms of frequency and severity of symptoms), and Ocular Surface Disease Index (OSDI) were evaluated. Seventy-four patients (79 eyes) were included, and the mean age was 56.8 \u00b1 17.3 years. The neurotrophic corneal ulcer was the most frequent disorder (n<\/i>\u00a0= 27, 34.2%), mainly for herpes virus (n<\/i>\u00a0= 15, 19.0%). The time of PRGF eye drops treatment associated with the RGTA matrix was 4.2 \u00b1 2.2 (1.5-9.0) months, and the follow-up period was 44.9 \u00b1 31.5 months. The ulcer closure was achieved in 76 eyes (96.2%). BCVA, VAS and OSDI improved from the baseline (p<\/i>\u00a0< 0.001), and IOP remained unchanged (p<\/i>\u00a0= 0.665). RGTA and PRGF in noninfectious ulcers were effective and could be a therapeutic alternative for this type of corneal disease.<\/p>\n<\/div>\n

Keywords:\u00a0<\/strong>PRGF; PRP; RGTA matrix; corneal ulcers; ocular surface diseases.<\/p>\n<\/div>\n<\/div>\n

[\/vc_column_text][vc_empty_space][vc_column_text]<\/p>\n

Figures<\/h3>\n

[\/vc_column_text][vc_empty_space][\/vc_column][\/vc_row][vc_row content_placement=”middle” content_text_aligment=”center”][vc_column]

\n\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t<\/div>\n<\/div>[vc_empty_space height=”50px”][\/vc_column][\/vc_row][vc_row][vc_column]\n T\u00e9l\u00e9charger l'article<\/span>\n <\/a>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

Vision (Basel). 2021 Jul 2;5(3):34.<\/strong> This study aimed to investigate the use of Plasma Rich in Growth Factors (PRGF) associated with tissue ReGeneraTing Agent (RGTA) drops for the treatment of noninfectious corneal ulcers<\/p>\n","protected":false},"author":1,"featured_media":19755,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[155],"tags":[405,406,407,408],"class_list":["post-20335","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medecine-regenerative","tag-apnea-fr","tag-implantologia-fr","tag-medicina-fr","tag-salud-fr"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/20335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/comments?post=20335"}],"version-history":[{"count":1,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/20335\/revisions"}],"predecessor-version":[{"id":36913,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/posts\/20335\/revisions\/36913"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/media\/19755"}],"wp:attachment":[{"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/media?parent=20335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/categories?post=20335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.btitrainingcenter.com\/fr\/wp-json\/wp\/v2\/tags?post=20335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}